Search results for "Dilator"

showing 10 items of 273 documents

Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed mai…

2004

Asthma guidelines suggest a stepwise approach to maintenance pharmacological treatment of persistent asthma until control is attained, and a 3 month review of the fixed maintenance dosing for step-up or step-down adjustment. This 12-week study compared the efficacy and safety of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler 160/4.5 or 80/4.5 microg) given as adjustable maintenance or fixed maintenance dosing. Patients (n = 2358) were randomised to budesonide/formoterol fixed maintenance dosing (two inhalations bid) or adjustable maintenance dosing (two inhalation bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inha…

AdultMalePulmonary and Respiratory MedicineBudesonidemedicine.drug_classDrug Administration ScheduleFormoterol FumarateBronchodilatormedicineHumansPharmacology (medical)DosingBudesonideathma; therapy; guidelinesAsthmaDose-Response Relationship DrugInhalationbusiness.industryNebulizers and VaporizersInhalerBiochemistry (medical)medicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

2013

Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and long-acting β2-agonists. To further explore the dose–response curve in asthma, we investigated the efficacy and safety of three different doses of tiotropium Respimat® as add-on to ICS in symptomatic patients with moderate persistent asthma. In this randomised, double-blind, placebo-controlled, four-way crossover study, patients were randomised to tiotro…

AdultMalePulmonary and Respiratory MedicineRespimatmedicine.drug_classScopolamine DerivativesPlaceboFEV1/FVC ratioDouble-Blind MethodCholinergic antagonistsBronchodilatorAdministration InhalationmedicineHumansTiotropium BromideAsthmaCross-Over StudiesDose-Response Relationship Drugbusiness.industryResearchTiotropiumTiotropium bromideMiddle AgedBronchodilator agentsmedicine.diseaseDose-ranging studyCrossover studyAsthmaRespimatrespiratory tract diseasesClinical trialAnesthesiaFemalebusinessmedicine.drugFollow-Up StudiesRespiratory Research
researchProduct

Inhaled Corticosteroids and the Beneficial Effect of Deep Inspiration in Asthma

2005

Deep inspiration-induced bronchoprotection and bronchodilation are impaired in asthma. We evaluated the effect of inhaled glucocorticosteroids on these phenomena. Two groups of subjects with asthma, 9 with moderate/severe hyperresponsiveness to methacholine, and 12 with mild/borderline hyperresponsiveness to methacholine, received inhaled fluticasone (880 microg daily) for 12 weeks. Serial bronchoprovocations were performed at Weeks 0, 6, and 12. The impact of deep inspirations on the airway response to methacholine was evaluated on the basis of inspiratory vital capacity and FEV(1). Fluticasone produced a wide spectrum of changes in the beneficial effects of deep inspiration, but the mean …

AdultMalePulmonary and Respiratory MedicineRespiratory Therapymedicine.drug_classVital CapacityRespiratory physiologySettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineSeverity of Illness IndexBronchial Provocation TestsBronchoconstrictor AgentsForced Expiratory VolumeIntensive careAdministration Inhalationlung inflation asthma treatmentBronchodilationmedicineHumansMethacholine ChlorideAgedFluticasoneAsthmaInhalationbusiness.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator AgentsA. Asthma and Allergyrespiratory tract diseasesAndrostadienesInhalationAnesthesiaRespiratory MechanicsFluticasoneCorticosteroidFemaleMethacholineBronchial Hyperreactivitybusinessmedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Exhaled Nitric Oxide Measurement Is Not Useful for Predicting the Response to Inhaled Corticosteroids in Subjects With Chronic Cough

2009

Background Increased concentrations of exhaled nitric oxide (ENO) are identified predominantly in subjects with chronic cough due to conditions that habitually respond well to therapy with inhaled corticosteroids (ICSs). The aim of this study was to assess the usefulness of ENO in predicting the response to ICS therapy in subjects with chronic cough and to determine the relationship between either methacholine or adenosine 5′-monophosphate (AMP) responsiveness and the response to ICS therapy. Methods A total of 43 patients with chronic cough were studied. During the baseline period, ENO measurement, spirometry, and concentration-response studies with both methacholine and AMP were performed…

AdultMalePulmonary and Respiratory MedicineSpirometryAdolescentmedicine.drug_classNitric OxideCritical Care and Intensive Care MedicineSensitivity and SpecificityBronchial Provocation TestsFluticasone propionatePredictive Value of TestsAdministration InhalationmedicineHumansProspective StudiesMethacholine ChlorideAgedFluticasoneInhalationmedicine.diagnostic_testbusiness.industryMiddle AgedAdenosine MonophosphateBronchodilator AgentsAndrostadienesChronic coughCoughROC CurveSpirometryAnesthesiaChronic DiseaseExhaled nitric oxideFluticasoneCorticosteroidFemaleMethacholinemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

The Lack of the Bronchoprotective and Not the Bronchodilatory Ability of Deep Inspiration Is Associated with Airway Hyperresponsiveness

2001

In healthy subjects, deep inspiration (DI) acts both as a bronchodilator and a bronchoprotector. The latter is impaired in asthmatics. We have now evaluated whether the lack of bronchoprotection is related to bronchial hyperresponsiveness (BHR), and whether the bronchodilatory effect is also lost in asthmatics. Ten healthy subjects (PC20 > 75 mg/ml), 12 asthmatics with moderate to severe BHR (PC20 < 1 mg/ml), 14 asthmatics with mild to borderline BHR (1 < PC20 < 25 mg/ml), and 10 rhinitics with mild to borderline BHR (1 < PC20 < 25 mg/ml) underwent single-dose methacholine provocations inducing at least 20% reduction in FEV1 after 20 min of DI inhibition. To measure the bronchodilatory effe…

AdultMalePulmonary and Respiratory MedicineSpirometryRhinitis Allergic Perennialmedicine.drug_classBronchoconstrictionSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineBronchial Provocation TestsFEV1/FVC ratioReference ValuesRisk FactorsForced Expiratory VolumeBronchodilatormedicineHumansReference ValueMethacholine ChlorideAsthmaBronchusmedicine.diagnostic_testbusiness.industryMiddle Agedrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesBronchial Provocation TestBronchodilatationmedicine.anatomical_structureInhalationBronchial hyperresponsivenessAnesthesiaFemaleMethacholineBronchial HyperreactivitybusinessHumancirculatory and respiratory physiologymedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Effect of Salmeterol on Seasonal Changes in Airway Responsiveness and Exhaled Nitric Oxide in Pollen-Sensitive Asthmatic Subjects

2002

Objective Using a model of natural allergen exposure, we examined the effect of regular treatment with salmeterol on allergen-induced changes in airway responsiveness and exhaled nitric oxide (ENO). Design Double-blind, randomized, parallel-group study. Setting Specialist allergy unit in a university hospital. Patients Asthmatic patients sensitized to pollen allergens were randomly allocated to monotherapy with salmeterol (n = 14) or placebo (n = 13). Interventions Salmeterol, 25 μg, and placebo inhalers, two puffs bid, for 6 weeks. Measurements Spirometry, the level of a provocative concentration of a substance (methacholine) causing a 20% fall in FEV 1 (PC 20 ), the PC 20 level for adenos…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyAdolescentmedicine.drug_classNitric OxideCritical Care and Intensive Care MedicinePlaceboDouble-Blind MethodForced Expiratory VolumeInternal medicineBronchodilatorAdministration InhalationmedicineHumansAlbuterolExpirationSalmeterol XinafoateAsthmamedicine.diagnostic_testbusiness.industryAirway ResistanceRhinitis Allergic SeasonalMiddle Agedrespiratory systemmedicine.diseaseAdenosine MonophosphateAsthmarespiratory tract diseasesEndocrinologyBreath TestsExhaled nitric oxideFemaleMethacholineSeasonsSalmeterolCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

The Effect of Spirometry on Bronchial and Alveolar Nitric Oxide in Subjects with Asthma

2013

The effect of spirometric maneuvers on exhaled nitric oxide (NO) at the constant flow rate of 50 ml/s (FE(NO)) has been studied with equivocal results. Furthermore, the effects of spirometry on bronchial NO flux (J'aw(NO)) and alveolar NO (CA(NO)), two measurements increasingly being used in clinical and research protocols, are unknown. The aim of this study was to evaluate the effect of spirometry on FE(NO), J'aw(NO), and CA(NO) in adults with asthma.Forty-four adults with asthma were studied. To assess the impact of exhaled NO measurement itself on exhaled NO values, FE(NO), J'aw(NO), and CA(NO) were obtained twice, at baseline and after a resting period of 10 min. Then spirometry (with o…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtymedicine.drug_classBronchiNitric OxideNitric oxidechemistry.chemical_compoundForced Expiratory VolumeInternal medicineBronchodilatormedicineHumansImmunology and AllergyAsthmamedicine.diagnostic_testConstant flowbusiness.industryrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesPulmonary AlveolichemistrySpirometryPediatrics Perinatology and Child HealthExhaled nitric oxideCardiologyFemalebusinessJournal of Asthma
researchProduct

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

2014

Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium. Methods Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks. The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo. R…

AdultMalePulmonary and Respiratory Medicinemedicine.drug_classVital CapacityScopolamine DerivativesHyperinflationQuinolonesPlaceboDrug Administration SchedulePulmonary Disease Chronic ObstructiveFunctional residual capacityDouble-Blind MethodForced Expiratory VolumeBronchodilatormedicineClinical endpointHumansLung volumesTiotropium BromideExerciseAgedCOPDCross-Over StudiesExercise Tolerancebusiness.industryChronic obstructive pulmonary diseaseTiotropiumQVA149Middle Agedmedicine.diseaseGlycopyrrolateCrossover studyBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeSpirometryAnesthesiaIndansIndacaterolFemaleLung Volume Measurementsbusinessmedicine.drugRespiratory Medicine
researchProduct

Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria

2011

Background The goal of asthma treatment is to achieve and maintain current best control and reduce future risk of exacerbations and long-term morbidity. Objective To prospectively compare current asthma control as defined by ACQ (asthma control questionnaire) and ACT (asthma control test) criteria with the GINA (Global Initiative for Asthma) classification in treated patients in a real-life setting. Methods In 150 adult patients (48% male, age 46.3 ± 14.4 years., forced expiratory volume in 1 second [FEV 1 ], 2.3 ± 0.9 L or 78.5 ± 21.8% pred.), asthma control was evaluated using the GINA classification as the "true" and ACQ-7, ACQ-5, and ACT as "predictor" criteria. The relationship between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaImmunologySensitivity and SpecificitySeverity of Illness IndexProspective evaluationPredictive Value of TestsForced Expiratory VolumeSurveys and QuestionnairesInternal medicineAsthma controlmedicineHumansImmunology and AllergyProspective StudiesAsthmaAdult patientsbusiness.industryMiddle Agedmedicine.diseasePredictive valueAsthmaBronchodilator Agentsrespiratory tract diseasesUncontrolled asthmaAsthma Control QuestionnairePhysical therapyFemalebusinessAnnals of Allergy, Asthma &amp; Immunology
researchProduct

Effect of intraarterial papaverine or nimodipine on vessel diameter in patients with cerebral vasospasm after subarachnoid hemorrhage.

2012

Papaverine (P) and nimodipine (N) are the most widely used vasodilators when angiographic and symptomatic vasospasm is present after subarachnoid aneurysmatic hemorrhage (SAH). Their effect is only short-lived and no direct comparisons have been undertaken to evaluate the action of both substances directly. We retrospectively assessed the effect of either P or N on angiographic diameter reduction and capillary blood flow.Fifteen SAH patients with secured aneurysms and cerebral vasospasm received intraarterial P, fifteen similar patients received N. As the primary endpoint, pre- and post-infusion arterial diameters and capillary blood flow were rated retrospectively on angiographies and comp…

AdultMaleSubarachnoid hemorrhageVasodilator AgentsIschemiaBrain IschemiaCerebral vasospasmModified Rankin ScalePapaverinemedicineHumansInfusions Intra-ArterialVasospasm Intracranialcardiovascular diseasesNimodipineAgedRetrospective StudiesAged 80 and overPapaverineAnalysis of Variancebusiness.industryVasospasmGeneral MedicineBlood flowCerebral ArteriesMiddle AgedSubarachnoid Hemorrhagemedicine.diseasenervous system diseasesCapillariesVasodilationAnesthesiaCerebrovascular CirculationSurgeryFemaleNimodipineNeurology (clinical)businessCarotid Artery Internalmedicine.drugBritish journal of neurosurgery
researchProduct